Literature DB >> 22836050

Pathophysiology and natural history of anorectal sequelae following radiation therapy for carcinoma of the prostate.

Eric K Yeoh1, Richard H Holloway, Robert J Fraser, Rochelle J Botten, Addolorata C Di Matteo, Julie Butters.   

Abstract

PURPOSE: To characterize the prevalence, pathophysiology, and natural history of chronic radiation proctitis 5 years following radiation therapy (RT) for localized carcinoma of the prostate. METHODS AND MATERIALS: Studies were performed in 34 patients (median age 68 years; range 54-79) previously randomly assigned to either 64 Gy in 32 fractions over 6.4 weeks or 55 Gy in 20 fractions over 4 weeks RT schedule using 2- and later 3-dimensional treatment technique for localized prostate carcinoma. Each patient underwent evaluations of (1) gastrointestinal (GI) symptoms (Modified Late Effects in Normal Tissues Subjective, Objective, Management and Analytic scales including effect on activities of daily living [ADLs]); (2) anorectal motor and sensory function (manometry and graded balloon distension); and (3) anal sphincteric morphology (endoanal ultrasound) before RT, at 1 month, and annually for 5 years after its completion.
RESULTS: Total GI symptom scores increased after RT and remained above baseline levels at 5 years and were associated with reductions in (1) basal anal pressures, (2) responses to squeeze and increased intra-abdominal pressure, (3) rectal compliance and (4) rectal volumes of sensory perception. Anal sphincter morphology was unchanged. At 5 years, 44% and 21% of patients reported urgency of defecation and rectal bleeding, respectively, and 48% impairment of ADLs. GI symptom scores and parameters of anorectal function and anal sphincter morphology did not differ between the 2 RT schedules or treatment techniques.
CONCLUSIONS: Five years after RT for prostate carcinoma, anorectal symptoms continue to have a significant impact on ADLs of almost 50% of patients. These symptoms are associated with anorectal dysfunction independent of the RT schedules or treatment techniques reported here. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22836050     DOI: 10.1016/j.ijrobp.2012.06.032

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

2.  Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer.

Authors:  Bradford S Hoppe; Jeff M Michalski; Nancy P Mendenhall; Christopher G Morris; Randal H Henderson; Romaine C Nichols; William M Mendenhall; Christopher R Williams; Meredith M Regan; Jonathan J Chipman; Catrina M Crociani; Howard M Sandler; Martin G Sanda; Daniel A Hamstra
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

3.  Can Anorectal Manometry Findings Predict Subsequent Late Gastrointestinal Radiation Toxicity in Prostate Cancer Patients?

Authors:  Yunseon Choi; Won Park; Poong-Lyul Rhee
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

4.  Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.

Authors:  Yoo-Kang Kwak; Sea-Won Lee; Chul Seung Kay; Hee Hyun Park
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

5.  Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review.

Authors:  Paul Sargos; Mame Daro Faye; Manon Bacci; Stéphane Supiot; Igor Latorzeff; David Azria; Tamim M Niazi; Te Vuong; Véronique Vendrely; Renaud de Crevoisier
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.